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gorithm and collecting costs based on the UK-specific
data. The percent of successfully treated patients was de-
rived from the clinical efficacy adjusted by the annual
persistency. RESULTS: The average total cost per patient
for twelve months of treatment for oxybutynin is £226
and £502 for tolterodine. The percent of successfully
treated patients after one year is 9.5% for oxybutynin
and 36.4% for tolterodine. The average cost-effective-
ness, expressed as cost per successfully treated patient, is
£2377 for oxybutynin and £1395 for tolterodine. CON-
CLUSION: Although the efficacy of oxybutynin and
tolterodine has been measured as equal, the persistency is
over three times higher with tolterodine. While the cost
of therapy for tolterodine is higher than oxybutynin, the
cost-effectiveness of tolterodine is superior. These results
were similar to the US-based model, but driven by the
different treatment approach to OAB in the UK.
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OBJECTIVES: To examine predictors of the decision to
use medication to treat patients newly diagnosed with
overactive bladder (OAB). METHODS: We conducted
an observational study in 217 patients newly diagnosed
with overactive bladder (OAB) enrolled by 32 physicians
nationwide (the ALZA Overactive Bladder Registry). In-
formation was collected on patient demographics, OAB
symptoms, quality of life and type of treatment recom-
mended—medication or behavioral. Treatment with medi-
cation was modeled in a stepwise logistic regression in
which patient age, sex, education level, race/ethnicity,
previous treatment, insurance status, duration of OAB
symptoms, frequency of urination, nocturia, number of
leakage accidents, physician severity rating, and symp-
tom bother were predictors. RESULTS: Participants were
on average 60.7 years old (S.D.  16.7), 82.4% female,
72.7% White, and had experienced OAB symptoms for
8.4 years (S.D.  12.0). They averaged 11 urinations per
day (S.D.  4.2), 2.7 at night (S.D.  1.6), and 1.9 acci-
dents a day (S.D.  3.0) with a mean bother score of 1.9
(S.D.  0.8), indicating “slight” bother. Significant pre-
dictors for treatment with medication were White race
(O.R.  4.6, 95% CI 1.9–11.4), number of accidents
(O.R.  1.2, 95% CI 1.0–1.5), physician OAB severity
ratings, both moderate (O.R.  3.3, 95% CI 1.4–8.0)
and severe (O.R.  3.8, 95% CI 1.0–14.6), college edu-
cation (O.R.  0.4, 95% CI 0.2–0.8), and prior use of
medication(s) (O.R.  3.2, 95% CI 1.2–9.0). Univariate
analyses indicated that Whites and Blacks received pre-
scriptions for OAB at comparable rates, while Asian and
Hispanic patients were much less likely to be prescribed
medication. CONCLUSIONS: Both demographic and
clinical variables are important predictors of the decision
to prescribe medication for overactive bladder. Among
clinical variables, only leakage accidents were associated
with the decision to prescribe medication.
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OBJECTIVE: To collect data on symptoms of bladder
dysfunction in a large German population sample of pa-
tients visiting primary care doctors, urologists or gyne-
cologists for any medical reason. METHODS: During a
total study period of approximately four months, a total
of 2,662 practices of primary care physicians, urologists
and gynecologists asked their visiting patients to fill out a
simple questionnaire consisting of four questions related
to symptoms of bladder dysfunction. The physicians were
asked to discuss the answers with their patients during
the same visit and to make a diagnosis. Based upon the
diagnosis, they were asked whether pharmacotherapy
would be initiated or the patient would be referred to a
specialist. RESULTS: Data of 198,230 patients were avail-
able for analysis. Overall, 22.4% reported symptoms at-
tributable to mixed and 8% to stress incontinence;
43.7% had no symptoms of bladder dysfunction. The
prevalence of symptoms attributable to overactive blad-
der was 25.9%, with the most commonly reported symp-
toms being frequency (41.9%), followed by urgency
(24.3%) and urge incontinence (20.2%). Doctor’s aware-
ness of symptoms was rather poor. Drugs for the treat-
ment of the symptoms of the overactive bladder were
prescribed by about 80% of the urologists; however,
only 40 to 45% of the gynecologists and the primary care
doctors considered this option. CONCLUSION: Consid-
ering the high prevalence of lower urinary tract symp-
toms in a growing elderly population and the impact on
the individual quality of life as well as the social system,
further educational efforts seem necessary to increase
awareness for this problem in the medical community. 
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